Filing summary
Registrant and period: The supplied filing is Cortexyme, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 1, 2021—not a Quince Therapeutics filing. The financial comparisons below are for full years, not Q4 alone.
Business context and reporting period
Cortexyme was a clinical-stage biotechnology company developing atuzaginstat (COR388), an oral gingipain inhibitor, principally for Alzheimer’s disease. Its GAIN Phase 2/3 trial was fully enrolled at 643 participants; other programs remained early-stage. The company had no approved products and had never generated product-sales revenue.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $61.3 million | $30.2 million |
| General and administrative expense | $17.6 million | $9.0 million |
| Net loss | $76.8 million | $37.0 million |
| Net loss per share, basic and diluted | $2.63 | $1.94 |
| Cash used in operating activities | $50.8 million | $33.3 million |
At December 31, 2020, cash and cash equivalents were $66.8 million, short-term investments $67.0 million, and long-term investments $50.5 million—$184.3 million combined. Current assets were $137.9 million versus current liabilities of $17.0 million. Total liabilities were $17.2 million, including lease liabilities; the filing reports no material borrowing debt. Accumulated deficit was $146.7 million. The company reported no product revenue, so revenue margins are not meaningful.
Financing activities provided $118.9 million in 2020, principally $117.6 million of net proceeds from a $125.0 million private placement, plus $1.3 million from option exercises. Investing activities used $52.4 million, primarily reflecting purchases and maturities of investments. Management said available cash, cash equivalents and investments were expected to fund planned operations through at least 2023, subject to assumptions and spending needs.
Material changes versus 2019
- Net loss more than doubled, rising 107.8%; R&D expense rose 102.9%, largely as GAIN trial costs and atuzaginstat manufacturing scaled up.
- G&A expense increased 96.4%, including higher personnel and public-company costs.
- Operating cash outflow increased by $17.5 million. The 2020 private placement strengthened the balance sheet but added 2.5 million shares; common shares outstanding increased from 26.9 million to 29.5 million.
- Interest income edged down 6.6% as investment yields declined.
Outlook, risks and unusual items
- In December 2020, an interim review of GAIN after approximately 300 participants reached six months led the independent monitoring committee to recommend continuing without a sample-size increase. This was not a report of definitive efficacy; topline results for the full 643-person, one-year study were expected in Q4 2021.
- On February 12, 2021, after year-end, the FDA imposed a partial clinical hold affecting the GAIN open-label extension following review of hepatic adverse events. Enrollment and dosing in the extension stopped, while participants in the randomized, double-blind portion continued assigned treatment. The company described the hepatic events as reversible and without known long-term adverse effects.
- Management expected to begin the COR588 clinical program and dose the first participant in the PEAK Parkinson’s study in Q3 2021. These were forward-looking plans, not completed milestones.
- Key risks include trial efficacy and safety outcomes, the FDA hold and regulatory decisions, dependence on atuzaginstat, future financing needs, reliance on contract manufacturers and clinical vendors, and potential COVID-19-related disruption. The company said it had drug supply for GAIN and had not experienced significant supply-chain disruption at the time of filing.
- The company reported no material litigation. The independent auditor issued an unqualified opinion on the financial statements and on internal control over financial reporting. A critical audit matter concerned estimation of prepaid and accrued clinical-trial expenses.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Cortexyme, Inc. (ticker CRTX), not Quince Therapeutics.
- Review subsequent disclosures on the FDA partial clinical hold, hepatic safety findings, and any effect on GAIN’s randomized phase or development plans.
- Check final GAIN efficacy and safety results against the stated endpoints and the interim continuation decision.
- Assess actual cash burn and remaining runway against management’s through-2023 estimate, including future trial, manufacturing, and pipeline costs.
- Track financing, share dilution, and equity-compensation overhang; 2020 stock-based compensation was $14.5 million.